BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 23683497)

  • 1. Activation of p53 with Nutlin-3a radiosensitizes lung cancer cells via enhancing radiation-induced premature senescence.
    Luo H; Yount C; Lang H; Yang A; Riemer EC; Lyons K; Vanek KN; Silvestri GA; Schulte BA; Wang GY
    Lung Cancer; 2013 Aug; 81(2):167-73. PubMed ID: 23683497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activation of p53 by Nutlin-3a, an antagonist of MDM2, induces apoptosis and cellular senescence in adult T-cell leukemia cells.
    Hasegawa H; Yamada Y; Iha H; Tsukasaki K; Nagai K; Atogami S; Sugahara K; Tsuruda K; Ishizaki A; Kamihira S
    Leukemia; 2009 Nov; 23(11):2090-101. PubMed ID: 19710698
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of p53 by nutlin-3a induces apoptosis and cellular senescence in human glioblastoma multiforme.
    Villalonga-Planells R; Coll-Mulet L; Martínez-Soler F; Castaño E; Acebes JJ; Giménez-Bonafé P; Gil J; Tortosa A
    PLoS One; 2011 Apr; 6(4):e18588. PubMed ID: 21483692
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol enhances ionizing radiation-induced premature senescence in lung cancer cells.
    Luo H; Wang L; Schulte BA; Yang A; Tang S; Wang GY
    Int J Oncol; 2013 Dec; 43(6):1999-2006. PubMed ID: 24141489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of p53-dependent senescence by the MDM2 antagonist nutlin-3a in mouse cells of fibroblast origin.
    Efeyan A; Ortega-Molina A; Velasco-Miguel S; Herranz D; Vassilev LT; Serrano M
    Cancer Res; 2007 Aug; 67(15):7350-7. PubMed ID: 17671205
    [TBL] [Abstract][Full Text] [Related]  

  • 6. p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells.
    Shen H; Maki CG
    J Cell Biochem; 2010 Dec; 111(5):1280-90. PubMed ID: 20803550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanisms of nutlin-induced apoptosis in multiple myeloma: evidence for p53-transcription-dependent and -independent pathways.
    Saha MN; Jiang H; Chang H
    Cancer Biol Ther; 2010 Sep; 10(6):567-78. PubMed ID: 20595817
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Radiosensitization of lung cancer by nutlin, an inhibitor of murine double minute 2.
    Cao C; Shinohara ET; Subhawong TK; Geng L; Kim KW; Albert JM; Hallahan DE; Lu B
    Mol Cancer Ther; 2006 Feb; 5(2):411-7. PubMed ID: 16505116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nutlin sensitizes lung carcinoma cells to interferon-alpha treatment in MDM2-dependent but p53-independent manner.
    Shuvalov O; Kizenko A; Shakirova A; Fedorova O; Petukhov A; Aksenov N; Vasileva E; Daks A; Barlev N
    Biochem Biophys Res Commun; 2018 Jan; 495(1):1233-1239. PubMed ID: 29175211
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of the p53 pathway by the MDM2 inhibitor nutlin-3a overcomes BCL2 overexpression in a preclinical model of diffuse large B-cell lymphoma associated with t(14;18)(q32;q21).
    Drakos E; Singh RR; Rassidakis GZ; Schlette E; Li J; Claret FX; Ford RJ; Vega F; Medeiros LJ
    Leukemia; 2011 May; 25(5):856-67. PubMed ID: 21394100
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells.
    Shen H; Maki CG
    J Biol Chem; 2010 Jul; 285(30):23105-14. PubMed ID: 20489208
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced transcriptional activity in the p53 pathway of senescent cells revealed by the MDM2 antagonist nutlin-3.
    Huang B; Vassilev LT
    Aging (Albany NY); 2009 Sep; 1(10):845-54. PubMed ID: 20157557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of lung p53 by Nutlin-3a prevents and reverses experimental pulmonary hypertension.
    Mouraret N; Marcos E; Abid S; Gary-Bobo G; Saker M; Houssaini A; Dubois-Rande JL; Boyer L; Boczkowski J; Derumeaux G; Amsellem V; Adnot S
    Circulation; 2013 Apr; 127(16):1664-76. PubMed ID: 23513067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks.
    Wang M; Morsbach F; Sander D; Gheorghiu L; Nanda A; Benes C; Kriegs M; Krause M; Dikomey E; Baumann M; Dahm-Daphi J; Settleman J; Willers H
    Cancer Res; 2011 Oct; 71(19):6261-9. PubMed ID: 21852385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nutlin-3 radiosensitizes hypoxic prostate cancer cells independent of p53.
    Supiot S; Hill RP; Bristow RG
    Mol Cancer Ther; 2008 Apr; 7(4):993-9. PubMed ID: 18413812
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiosensitization of wildtype p53 cancer cells by the MDM2-inhibitor PXN727 is associated with altered heat shock protein 70 (Hsp70) levels.
    Schilling D; Düwel M; Molls M; Multhoff G
    Cell Stress Chaperones; 2013 Mar; 18(2):183-91. PubMed ID: 22933182
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer.
    Deben C; Wouters A; Op de Beeck K; van Den Bossche J; Jacobs J; Zwaenepoel K; Peeters M; Van Meerbeeck J; Lardon F; Rolfo C; Deschoolmeester V; Pauwels P
    Oncotarget; 2015 Sep; 6(26):22666-79. PubMed ID: 26125230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nutlin-3, an Antagonist of MDM2, Enhances the Radiosensitivity of Esophageal Squamous Cancer with Wild-Type p53.
    He T; Guo J; Song H; Zhu H; Di X; Min H; Wang Y; Chen G; Dai W; Ma J; Sun X; Ma J
    Pathol Oncol Res; 2018 Jan; 24(1):75-81. PubMed ID: 28341911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.